The Effect of Coleus Forskohlii Extract on the Risk Factors of Metabolic Syndrome

Investigation of Appetite Suppressant Properties Associated With Coleus Forskohlii in Overweight and Obese Individuals

Status

UNKNOWN

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02143349

Enrollment

Registered

2014-05-21

Start date

2014-04-30

Completion date

2015-05-31

Last updated

2014-05-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metabolic Syndrome, Obesity

Keywords

obesity, herbal remedies, metabolic disorders

Brief summary

Coleus forskohlii extract contains the bioactive compound, forskolin. Preliminary studies have shown that forskolin can increase fat metabolism thus reduce fat accumulation in both animals and humans. It has been suggested that forskolin may also suppress appetite thus reduce energy intake and results in weight loss. This study will evaluate the appetite suppressant properties of Coleus forskohlii extract. In addition the effect on central obesity and risk factors of metabolic syndrome will also be investigated.

Interventions

DIETARY_SUPPLEMENTColeus forskohlii extract

Ingestion of 250 mg Coleus forskohlii extract capsule twice a day for 12 weeks

OTHERPlacebo

Ingestion of 250 mg placebo capsule twice a day for 12 weeks

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

20 Years to 60 Years

Healthy volunteers

Inclusion criteria

* Both Australian males and females, age 20-60 years, Overweight or obese (BMI \>25), waist circumference of \> 94 cm (male), waist circumference of \>80 cm (female)

Exclusion criteria

* Cigarette smoker, hypertension, all types of heart, liver and kidney disease, pregnancy, lactating, Type 1 diabetes and weight loss medication.

Design outcomes

Primary

Measure	Time frame
changes in appetite will be assessed using visual analogue scale; blood hormone levels will also be measured using commercial kits.	Baseline and 12 weeks

Secondary

Measure	Time frame
reduction in central obesity - waist circumference will be measured on fortnight basis	12 weeks

Other

Measure	Time frame
alterations in blood lipids. This will be measured using commercial kits	12 weeks

Countries

Australia

Contacts

Primary ContactDr. Xiao Su

xiao.su@vu.edu.au+61399192318

Backup ContactDr HN Shivaprasad

shiv@olivelifesciences.com918971489704

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026